Longitudinal Molecular Profiling in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Background: Somatic mutations in isocitrate dehydrogenase 1 (IDH1) are reported in 6-10% of patients (pts) with acute myeloid leukemia (AML), resulting in production of the oncometabolite D-2-hydroxyglutarate. Ivosidenib (IVO) is an oral, potent, targeted inhibitor of mutant IDH1 (mIDH1) and is FDA-...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2020-11, Vol.136 (Supplement 1), p.2-3
Hauptverfasser:	Choe, Sung, Wang, Hongfang, Roboz, Gail J., DiNardo, Courtney D., Stein, Eytan M., Mims, Alice S., Prince, Gabrielle T., Watts, Justin M., Fan, Bin, Nejad, Parham, Zhang, Vickie, Liu, Hua, Attar, Eyal C., Wu, Bin, Stone, Richard M.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!